Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Trevi Therapeutics Inc
TRVI | US
13.50
USD-0.45
-3.23%
TRVI | US
About Trevi Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
13.50
Open
13.92
High
13.95
Low
13.42
Trevi Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio an oral extended-release formulation of nalbuphine which is in phase 2b/3 clinical trial for the treatment of chronic pruritus chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven Connecticut.
View LessTRVI | US
Risk
46.4
Sharpe
1.64
Luna's Score
54/100
Recommendation
Hold
Luna says (TRVI | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
37.3%1 month
46.4%3 months
54.7%6 months
56.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.42
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
-4.92
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-43.03M
MarketCap
979.99M
MarketCap(USD)
979.99M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-48.09
Short ratio
3.46
Short perc.
3.34
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.63
Range1M
2.67
Range3M
5.87
Volumes: Market Activity
Rel. volume
0.70
Price X volume
12.50M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.92 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.42 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 54.71 | - | Lower Risk |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 979.99M | - | Emerging |
